Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 14/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 14/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 14/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 14/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14411790 | 1.00 | PDK1 (0.39) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL15374902 | 1.00 | PDK1 (0.39) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL9818516 | 0.79 | TSHR (0.44) | ALDH1A1TSHR | |
| SCHEMBL568924 | 0.78 | ALDH1A1 (0.53) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL569205 | 0.78 | ALDH1A1 (0.53) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL568925 | 0.78 | ALDH1A1 (0.53) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL31398303 | 0.73 | TSHR (0.39) | ALDH1A1TSHR | |
| SCHEMBL2889294 | 0.73 | PDK1 (0.38) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL5737910 | 0.73 | PDK1 (0.39) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL13543292 | 0.73 | PDK1 (0.38) | PDK1PDK2PDK3PDK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024112830-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4347033-A1 | HYDROXY AND (HALO)ALKOXY SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347031-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347583-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347032-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11839476-B2 | Bio-electrode composition, bio-electrode, and method for manufacturing a bio-electrode | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-12 | — | — | US | disclosed |
| US-20230009251-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| WO-2022256622-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256702-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256660-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| US-7307173-B1 | Pyrroline chromophores | UNIVERSITY OF WASHINGTON (US) | 2007-12-11 | — | — | US | disclosed |
| US-7084283-B2 | Synthesis of fluorinated molecules possesing high optical non-linearity | LOCKHEED MARTIN CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-7078542-B2 | Nonlinear optical compounds and methods for their preparation | UNIVERSITY OF WASHINGTON (US) | 2006-07-18 | — | — | US | disclosed |
| US-7014796-B2 | Nonlinear optical compounds and methods for their preparation | UNIVERSITY OF WASHINGTON (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050023507-A1 | pi-electron donor group bonded to a pi-electron conjugated bridge group bonded to a mono- or dicyanodihydrofuran acceptor; large hyperpolarizability, dipole moment, and electrooptic coefficients; electrooptics | UNIVERSITY OF WASHINGTON (US) | 2005-02-03 | — | — | US | disclosed |
| US-20040158084-A1 | Synthesis of fluorinated molecules possesing high optical non-linearity | LOCKHEED MARTIN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004065384-A1 | NONLINEAR OPTICAL COMPOUNDS AND METHODS FOR THEIR PREPARATION | UNIVERSITY OF WASHINGTON (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040135130-A1 | Nonlinear optical compounds and methods for their preparation | UNIVERSITY OF WASHINGTON | 2004-07-15 | — | — | US | disclosed |
| WO-2002076969-A1 | SYNTHESIS OF FLUORINATED MOLECULES POSSESSING HIGH OPTICAL NON-LINEARITY | LOCKHEED MARTIN CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050023507-A1 | pi-electron donor group bonded to a pi-electron conjugated bridge group bonded to a mono- or dicyanodihydrofuran acceptor; large hyperpolarizability, dipole moment, and electrooptic coefficients; electrooptics | PCNA, ETFA, POF1B | PDK1 105/4885PDK2 296/4885PDK3 268/4885 |
| US-20230009251-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN2B | PDK1 4120/4885PDK2 3775/4885PDK3 3486/4885 |
| US-11839476-B2 | Bio-electrode composition, bio-electrode, and method for manufacturing a bio-electrode | AFF1, AFF4, AFF2 | PDK1 3361/4885PDK2 2410/4885PDK3 1608/4885 |
| US-20040158084-A1 | Synthesis of fluorinated molecules possesing high optical non-linearity | QRFPR, NONO, PARG | PDK1 3590/4885PDK2 3744/4885PDK3 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.